Protara Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -29.2% | -29.2% | -27.4% |
| FY2022 | -64.6% | -64.6% | -58.2% |
| FY2023 | -59.2% | -59.2% | -51.2% |
| FY2024 | -26.7% | -26.7% | -24.6% |
| FY2025 | -29.2% | -29.2% | -27.4% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -29.2% | -29.2% | -27.4% |
| FY2022 | -64.6% | -64.6% | -58.2% |
| FY2023 | -59.2% | -59.2% | -51.2% |
| FY2024 | -26.7% | -26.7% | -24.6% |
| FY2025 | -29.2% | -29.2% | -27.4% |